Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
Filings by filing date
News
Biz Brief
Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Kintyre House, 209 Govan Road GLASGOW G51 1HJ |
Tel: | N/A |
Website: | N/A |
IR: | N/A |
Key People | ||
Constantinos Zertalis Chairman of the Board | Paraskevi Pylarinou Chief Financial Officer, Secretary, Director | Georgios Thrapsaniotis Treasurer, Director |
Business Overview |
Omed, Inc., formerly Optecmed, Inc., is focused on disruptive technologies in the fields of digital health, prosthetics, orthotics, diabetes, assistive devices, sports and wellbeing, and deep vein thrombosis (DVT). It has developed sensing technology under the brand name Flexisense, which uses a multitude of micro sensors to detect pressure as well as shear. It is also focusing on the fields of prosthetics and orthotics (P&O) and diabetic foot clinics in Europe. It holds a wholesale license for medicinal products for human use through C-Pharm, Ltd. It trades pharmaceutical products to wholesalers and manufacturers around the world. It also supplies medical consumables to cruise ships and merchant vessels. Its subsidiaries include C-Pharm, Ltd., HCi Viocare Technologies Limited and HCi Viocare Clinics UK Limited. Its HCi Viocare Technologies is developing hardware solutions focusing on providing on demand information in the fields of digital health, prosthetics, orthotics and DVT. |
Financial Overview |
For the three months ended 31 March 2019, Omed Inc revenues decreased 59% to $54K. Net loss decreased 10% to $622K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development decrease of 29% to $59K (expense), Depreciation decrease of 23% to $15K (expense), Professional fees decrease of 9% to $18K (expense). |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $0.09M as of Mar 31, 2019 |
Annual revenue (TTM): | $0.34M as of Mar 31, 2019 |
EBITDA (TTM): | -$4.08M as of Mar 31, 2019 |
Net annual income (TTM): | -$5.78M as of Mar 31, 2019 |
Free cash flow (TTM): | -$0.51M as of Mar 31, 2019 |
Net Debt Last Fiscal Year: | $0.08M as of Mar 31, 2019 |
Shares outstanding: | 122,022,796 as of Mar 31, 2022 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |